

First reports of adverse drug reactions and drug interactions

© Springer Nature Switzerland AG 2022

Table 1 contains an overview of first published case reports of adverse drug reactions and interactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries

of adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

Table 1 First reports of adverse drug reactions or drug interactions

Drug: event	References
Adverse drug reactions	
Abatacept: disseminated superficial porokeratosis (serious)	Klager S, et al. Abatacept-induced disseminated superficial porokeratosis. <i>J Clin Rheumatol.</i> 2021;27(8S):S634-5
Cytisinicline: urticaria	Campagnari S, et al. Cytisine induced urticaria: a case report during a smoking cessation treatment. <i>Acta Biomed.</i> 2022;93(Suppl 1):e2022073
Epirubicin: punctured skin damage	Guan Y, et al. Epirubicin-loaded beads transarterial prostatic arterial chemoembolization is a promising treatment for advanced prostate cancer with lower urinary tract obstruction or hematuria—a case series report. <i>Transl Androl Urol.</i> 2022; 11(4):480-94
Milnacipran: spontaneous erection	Avci SH, et al. Milnacipran-induced spontaneous erection [abstract 0429]. <i>Psychiatry Clin Psychopharmacol.</i> 2017;27(Suppl 1):148
Minoxidil: pityriasis amiantacea	Wu AG, et al. Manifestation of pityriasis amiantacea following initiation of minoxidil. <i>JAAD Case Rep.</i> 2022;24:94-6
Palbociclib: dermatomyositis (serious)	Jfri A, et al. LB932 dermatomyositis following treatment with cyclin-dependent kinases inhibitors: a single-center retrospective cohort study. <i>J Invest Dermatol.</i> 2022;142(8 Suppl):B14
Paliperidone: idiopathic granulomatous mastitis (serious)	Marques MC, et al. Idiopathic granulomatous mastitis associated with paliperidone. <i>Gazz Med Ital Arch Sci Med.</i> 2022;181(1):90-4
Tozinameran: multifocal motor neuropathy (serious)	Eren F, et al. Multifocal motor neuropathy after SARS-CoV-2 vaccination: a causal or coincidental association? <i>J Int Med Res.</i> 2022;50(7):3000605221110709
Zimberelimab: ocular myopathy and myasthenia gravis (serious)	Kim H, et al. Concurrent ocular myopathy and myasthenia gravis after zimberelimab therapy in a patient with non-small-cell lung cancer. <i>J Clin Neurol.</i> 2022;1(3):364-6
Drug interactions	
Anticoagulants + dronedarone interaction: intracerebral haemorrhage (serious)	Vio R, et al. Safety and efficacy of direct oral anticoagulants in patients with atrial fibrillation on concomitant treatment with dronedarone [abstract no. 40551]. <i>EP Europace.</i> 2022;24(Suppl 1):i425-7
Berberine + hemp: long QT syndrome and torsades de pointes (serious)	Deleaval M, et al. Harmless herbs? A case report of acquired long QT syndrome and torsades de pointes in a patient taking herbal supplements. <i>HeartRhythm Case Rep.</i> 2022;8(5):309-12

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage